ZS Pharma Announces Start Of Enrollment Of Phase 3 Extended Dosing Study Of ZS-9 In Patients With Hyperkalemia
Published: Mar 25, 2014
COPPELL, Texas--(BUSINESS WIRE)--ZS Pharma, a specialty pharmaceutical company developing novel treatments for kidney, cardiovascular and liver disorders, today announced that it has begun enrolling patients in ZS004, its second Phase 3 clinical trial of ZS-9, a novel investigational treatment for hyperkalemia. This randomized, double-blind, placebo-controlled study is designed to confirm, over a longer treatment period, the positive results previously reported for ZS003, a Phase 3 trial in which a once-daily dose of ZS-9 (5g or 10g) maintained potassium levels within the normal range with safety and tolerability similar to placebo.
Help employers find you! Check out all the jobs and post your resume.